Graeme Martin, PhD is a pharmaceutical industry veteran with more 40 years of multinational Pharma and Biotech R&D experience in Europe, USA and Japan.
In 2017, he founded HatchBox Bioconsulting, LLC, an independent life science advisory providing strategic guidance to foster early stage life science innovation. Prior to this, he was President and CEO of Takeda Ventures, Inc., the corporate venture arm of Takeda Pharmaceuticals. During a tenure of 14 years, he oversaw strategic investments into a portfolio of 31 early stage companies representing >$100mm under management. He served on the Board of 16 of these companies.
Before turning to corporate venture, Dr. Martin held senior R&D positions at Roche (USA), GlaxoWellcome (UK) and Wellcome Research Laboratories (UK), where he led a number of therapeutic discovery initiatives resulting in three IND submissions and ultimately, the launch of Zomig®, marketed worldwide for the acute treatment of migraine. He is the author of more than 85 peer reviewed scientific papers and book chapters.
He received his Bachelor of Science degree in Pharmacology from the University of Bath, and his doctorate from University College, London, UK.